Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 60 EXECUTIVE BLVD FARMINGDALE NY 11735 |
Tel: | 1-212-5323232 |
Website: | https://www.enzo.com |
IR: | See website |
Key People | ||
Steven J. Pully Chairman of the Board | Kara Cannon Chief Executive Officer, Chief Operating Officer | Patricia Eckert Chief Financial Officer | Matthew Kupferberg General Counsel, Secretary |
Business Overview |
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide. |
Financial Overview |
For the six months ended 31 January 2024, Enzo Biochem Inc revenues increased 12% to $16.4M. Net loss before extraordinary items decreased 21% to $6.5M. Revenues reflect Europe segment increase of 6% to $4.4M. Lower net loss reflects Corporate & Other segment loss decrease of 31% to $7.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.17 to -$0.13. |
Employees: | 179 as of Jul 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $32.80M as of Jan 31, 2024 |
EBITDA (TTM): | -$16.32M as of Jan 31, 2024 |
Net annual income (TTM): | -$23.31M as of Jan 31, 2024 |
Free cash flow (TTM): | -$45.92M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 51,225,734 as of Mar 11, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |